give beat boy rais
net dbt
strong top-lin bottom-lin beat
report revenu ahead consensu adjust
ep beat consensu product sale reduc expens
rais full year guidanc revenu
adjust ep continu share repurchas program
buy back commit anoth lieu
buy-back still see ampl firepow capit alloc pipelin
develop adjust non-gaap ep accordingli rais po
multipl in-lin major biopharma peer reiter buy
growth new product off-set declin legaci
declin legaci product off-set growth new on-going launch
enbrel sale miss consensu project y-o-i declin
enbrel sale given slight decreas net price volum neulasta sale
came consensu expect continu onpro
util current make us unit recent launch
eu prolia continu deliv remain signific growth driver gain
share world-wide esa franchis decreas due lower net sell price increas
competit aimovig launch strong gate driven patient demand
physician adopt evidenc nearli cumul nbrx end june
overal pleas perform key product
sean harper execut vice presid research develop toni hooper
execut vice presid commerci oper announc retir
dr harper pursu opportun early-stag biotech replac dr
david rees current senior vice presid translat scienc oncolog mr
hooper replac murdo gordon former chief commerci offic
septemb view execut success commerci
organ repres continu amgn current busi strategi
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
biopharmaceut compani
develop manufactur market biolog
therapi oncolog inflamm
five key market product among top
sell pharmaceut product world
collect revenu
buy rate base new product launch
anticip biosimilar launch
help drive top-lin growth strong
cash posit also allow addit share
buyback dividend payment transform
price object base multipl ep estim
non-gaap ep exclud stock option expens amort intang asset
restructur charg non-cash expens multipl support
strong cash flow gener dividend payout choic multipl
line major pharma peer
downsid risk po greater-than-forecast declin esa neupo
enbrel revenu greater-than-expect price pressur europ potenti drug
price system restructur us failur bring new pipelin product
upsid risk po less-than-forecast declin key product revenu
ying huang herebi certifi view express research report accur
reflect person view subject secur issuer also certifi
part compens directli indirectli relat specif
recommend view express research report
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
